FGFR1 gene is amplified in 14% of HR+/ HER2- breast cancer patients. Efficacy and safety of lucitanib, an inhibitor of VEGFR1-3, FGFR1-3 and PDGFRα/β, were assessed.
Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study
Lambertini, Matteo;
2019-01-01
Abstract
FGFR1 gene is amplified in 14% of HR+/ HER2- breast cancer patients. Efficacy and safety of lucitanib, an inhibitor of VEGFR1-3, FGFR1-3 and PDGFRα/β, were assessed.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
354.full.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
541.4 kB
Formato
Adobe PDF
|
541.4 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
